Presentation is loading. Please wait.

Presentation is loading. Please wait.

Preemptive Pharmacogenomic Testing for Precision Medicine

Published byAllison Gilbert Modified over 5 years ago

Similar presentations

Presentation on theme: "Preemptive Pharmacogenomic Testing for Precision Medicine"— Presentation transcript:

1 Preemptive Pharmacogenomic Testing for Precision Medicine
Yuan Ji, Jennifer M. Skierka, Joseph H. Blommel, Brenda E. Moore, Douglas L. VanCuyk, Jamie K. Bruflat, Lisa M. Peterson, Tamra L. Veldhuizen, Numrah Fadra, Sandra E. Peterson, Susan A. Lagerstedt, Laura J. Train, Linnea M. Baudhuin, Eric W. Klee, Matthew J. Ferber, Suzette J. Bielinski, Pedro J. Caraballo, Richard M. Weinshilboum, John L. Black  The Journal of Molecular Diagnostics  Volume 18, Issue 3, Pages (May 2016) DOI: /j.jmoldx Copyright © 2016 American Society for Investigative Pathology and the Association for Molecular Pathology Terms and Conditions

2 Figure 1 The RIGHT Protocol study design with a focus on five PGx genes. CDS, clinical decision support; EMR, electronic medical record; NGS, next-generation sequencing; PGx, pharmacogenomics; QC, quality control; RIGHT, Right Drug, Right Dose, Right Time–Using Genomic Data to Individualize Treatment. The Journal of Molecular Diagnostics  , DOI: ( /j.jmoldx ) Copyright © 2016 American Society for Investigative Pathology and the Association for Molecular Pathology Terms and Conditions

3 Figure 2 Distributions of RIGHT subjects in CYP2D6, CYP2C9, CYP2C19, SLCO1B1*5, and VKORC1 categories. Percentage of subjects among the total RIGHT cohort for each of the predicted CYP2D6 (A), CYP2C9 (B), and CYP2C19 (C) metabolizer groups; percentage of subjects among the total RIGHT cohort carrying various genotypes for SLCO1B1*5 (TT, TC, or TT) and VKORC1 SNP rs (GG, GA, and AA) (D). EM, extensive metabolizer; IM, intermediate metabolizer; PM, poor metabolizer; RIGHT, Right Drug, Right Dose, Right Time–Using Genomic Data to Individualize Treatment; UM, ultrarapid metabolizer. The Journal of Molecular Diagnostics  , DOI: ( /j.jmoldx ) Copyright © 2016 American Society for Investigative Pathology and the Association for Molecular Pathology Terms and Conditions

4 Figure 3 Percentage of RIGHT subjects among groups carrying actionable PGx variants in zero to five of the PGx genes. PGx, pharmacogenomics; RIGHT, Right Drug, Right Dose, Right Time–Using Genomic Data to Individualize Treatment. The Journal of Molecular Diagnostics  , DOI: ( /j.jmoldx ) Copyright © 2016 American Society for Investigative Pathology and the Association for Molecular Pathology Terms and Conditions

5 Figure 4 Examples of CYP2C19 CDS alerts triggered for the RIGHT subjects at the point of care. A: Patient predicted to carry one single actionable PGx variant-triggered alert for one medication, clopidogrel. B: Patient predicted to carry one single actionable PGx variant-triggered alerts for two medications, codeine and tramadol. C: Patient predicted to carry actionable PGx variants in two genes that triggered alerts for several relevant drugs. CDS, clinical decision support; MICS, Mayo Integrated Clinical Systems; PGx, pharmacogenomics; RIGHT, Right Drug, Right Dose, Right Time–Using Genomic Data to Individualize Treatment. The Journal of Molecular Diagnostics  , DOI: ( /j.jmoldx ) Copyright © 2016 American Society for Investigative Pathology and the Association for Molecular Pathology Terms and Conditions

Download ppt "Preemptive Pharmacogenomic Testing for Precision Medicine"

Similar presentations

Measurement of Relative Copy Number of CDKN2A/ARF and CDKN2B in Bladder Cancer by Real-Time Quantitative PCR and Multiplex Ligation-Dependent Probe Amplification.

Measurement of Relative Copy Number of CDKN2A/ARF and CDKN2B in Bladder Cancer by Real-Time Quantitative PCR and Multiplex Ligation-Dependent Probe Amplification.
Nine Novel Germline Gene Variants in the RET Proto-Oncogene Identified in Twelve Unrelated Cases Syed A. Ahmed, Karen Snow-Bailey, W. Edward Highsmith,

Nine Novel Germline Gene Variants in the RET Proto-Oncogene Identified in Twelve Unrelated Cases Syed A. Ahmed, Karen Snow-Bailey, W. Edward Highsmith,
CyclinD1/CyclinD3 Ratio by Real-Time PCR Improves Specificity for the Diagnosis of Mantle Cell Lymphoma Carol D. Jones, Katherine H. Darnell, Roger A.

CyclinD1/CyclinD3 Ratio by Real-Time PCR Improves Specificity for the Diagnosis of Mantle Cell Lymphoma Carol D. Jones, Katherine H. Darnell, Roger A.
Design and Multiseries Validation of a Web-Based Gene Expression Assay for Predicting Breast Cancer Recurrence and Patient Survival Ryan K. Van Laar The.

Design and Multiseries Validation of a Web-Based Gene Expression Assay for Predicting Breast Cancer Recurrence and Patient Survival Ryan K. Van Laar The.
PGx Logical Overview.

PGx Logical Overview.
TOWARDS ELECTRONIC PHARMACOGENOMIC ASSISTANCE AND TRANSLATION SERVICES

TOWARDS ELECTRONIC PHARMACOGENOMIC ASSISTANCE AND TRANSLATION SERVICES
Enzymes involved in drug metabolism

Enzymes involved in drug metabolism
Development of a Next-Generation Sequencing Method for BRCA Mutation Screening  Maurice Chan, Shen Mo Ji, Zhen Xuan Yeo, Linda Gan, Eric Yap, Yoon Sim.

Development of a Next-Generation Sequencing Method for BRCA Mutation Screening  Maurice Chan, Shen Mo Ji, Zhen Xuan Yeo, Linda Gan, Eric Yap, Yoon Sim.
Assessment of Target Enrichment Platforms Using Massively Parallel Sequencing for the Mutation Detection for Congenital Muscular Dystrophy  C. Alexander.

Assessment of Target Enrichment Platforms Using Massively Parallel Sequencing for the Mutation Detection for Congenital Muscular Dystrophy  C. Alexander.
Statistical Considerations for Immunohistochemistry Panel Development after Gene Expression Profiling of Human Cancers  Rebecca A. Betensky, Catherine.

Statistical Considerations for Immunohistochemistry Panel Development after Gene Expression Profiling of Human Cancers  Rebecca A. Betensky, Catherine.
Targeted Next-Generation Sequencing for Hereditary Cancer Syndromes

Targeted Next-Generation Sequencing for Hereditary Cancer Syndromes
In Silico Proficiency Testing for Clinical Next-Generation Sequencing

In Silico Proficiency Testing for Clinical Next-Generation Sequencing
Laboratory Guidelines for Detection, Interpretation, and Reporting of Maternal Cell Contamination in Prenatal Analyses  Narasimhan Nagan, Nicole E. Faulkner,

Laboratory Guidelines for Detection, Interpretation, and Reporting of Maternal Cell Contamination in Prenatal Analyses  Narasimhan Nagan, Nicole E. Faulkner,
The Spectrum of CFTR Variants in Nonwhite Cystic Fibrosis Patients

The Spectrum of CFTR Variants in Nonwhite Cystic Fibrosis Patients
Eligibility Criteria and Genetic Testing Results from a High-Risk Cohort for Hereditary Breast and Ovarian Cancer Syndrome in Southeastern Ontario  Ricardo.

Eligibility Criteria and Genetic Testing Results from a High-Risk Cohort for Hereditary Breast and Ovarian Cancer Syndrome in Southeastern Ontario  Ricardo.
Diagnostic Application of an Extensive Gene Panel for Leber Congenital Amaurosis with Severe Genetic Heterogeneity  Moon-Woo Seong, Soo Hyun Seo, Young.

Diagnostic Application of an Extensive Gene Panel for Leber Congenital Amaurosis with Severe Genetic Heterogeneity  Moon-Woo Seong, Soo Hyun Seo, Young.
Validation and Comparison of Pharmacogenetics-Based Warfarin Dosing Algorithms for Application of Pharmacogenetic Testing  Nitin Roper, Barry Storer,

Validation and Comparison of Pharmacogenetics-Based Warfarin Dosing Algorithms for Application of Pharmacogenetic Testing  Nitin Roper, Barry Storer,
Cystic Fibrosis The Journal of Molecular Diagnostics

Cystic Fibrosis The Journal of Molecular Diagnostics
Molecular Genetics of Pediatric Soft Tissue Tumors

Molecular Genetics of Pediatric Soft Tissue Tumors
Rapid Genotyping of Single Nucleotide Polymorphisms Influencing Warfarin Drug Response by Surface-Enhanced Laser Desorption and Ionization Time-of-Flight.

Rapid Genotyping of Single Nucleotide Polymorphisms Influencing Warfarin Drug Response by Surface-Enhanced Laser Desorption and Ionization Time-of-Flight.

Similar presentations

Ads by Google